






286A ABSTRACTS- Myocardial Ischemia and Infarction 
1026-48 Increased Serum Levels  of  Macrophage Migration 
Inh ib i tory  Factor-Related Prote in Is a Sens i t ive  Marker 
fo r  Acute Coronary Syndrome in Patients With 
Coronary Artery Disease 
Shoichi Mivamoto. Masaki-lkemoto, Koji Hasegawa, Noritoshi Nagaya, Shun-ichi Tamaki, 
Kunihisa Miwa, Masatoshi Fujita, Department of Cardiovascular Medicine, Graduate 
School of Medicine, Kyoto Universi~ Kyoto, Japan, College of Medical Technology, 
Kyoto Universi~ Kyoto, Japan. 
Background: In patients with coronary artery disease (CAD), it is important to discrimi- 
nate acute coronary syndrome (ACS). There is accumulating data that ACS relates to 
recent activation of inflammation affecting atherosclerotic plaques, Macrophage migra- 
tion inhibitory factor-related protein (MRP) is a calcium-binding protein (heterodimer), 
which is expressed in infiltrate macrophages during inflammatory reactions. The purpose 
of this study was to investigate whether MRP is useful for the diagnosis of ACS. Meth- 
ods: We studied 92 patients with angiographically proven CAD. They comprised two 
groups [Group ACS, Braunwald's subclass II or lit of unstable angina, and acute myocar- 
dial infarction, n=53; Group SA, stable angina, n=39]. We purified MRP from human leu- 
kecytes and then prepared rabbit moneclonal antibodies against the MRP. Serum 
concentrations of MRP were measured using a newly-developed enzyme-linked immun- 
osorbent assay system. In addition, we measured serum concentrations of C-reactive 
protein (CRP). Results: There were no significant differences in age, gender and core- 
nan/risk factors between the two groups. Serum MRP levels were significantly higher in 
Group ACS than in Group SA [3,25±3,08 (SD) microgram/ml vs. 0.77:L-0.31 microgram/ 
ml, p < 0.0001]. Serum CRP levels were also significantly higher in Group ACS than in 
Group SA (3.11±6.14 mg/dl vs. 0.19~0.20 mg/dl, p=0.0039). Sensitivity and specificity of 
positive serum MRP levels (> 1.2 microgram/ml) for detection of ACS were 84,9% and 
89.7%, respectively. On the other hand, sensitivity and specificity of positive serum CRP 
levels (> 0.5rag/all) for detection of ACS were 52.8% and 92.3%, respectively. Sensitivity 
was significantly (p < 0.05) higher in the measurements of MRP than in the measure- 
ments of CRP, while specificity was comparable in the two markers. Conclusion: The 
measurement.of serum MRP levels is useful for the discrimination of ACS in patients with 
CAD. 
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1027-38 A Randomized Comparison of the Ef fects  of  C lop idogre l  
and Aspirin on Thrombotic Variables and C-Reactive 
Protein Following Myocardial Infarction 
Mark Woodward, Gordon D. Lowe, Lesley M. Francis, Ann Rumley, Stuart Cobbe, 
Institute for International Health, University of Sydney, Sydney, Australia, Departments of 
Medicine and Medical Cardiology, Glasgow, United Kingdom. 
Background: Previous randomised trials have shown clopidogrel to be more efficacious 
than aspidn in the prevention of ischemic events amongst those at high-risk. The com- 
parative effect of these agents on thrombotic variables and C-reactive protein remains 
unknown. 
Methods: 184 men and women, recruited from hospitals in the United Kingdom, were 
raodomisad to 75rag/day of either clopidogrsl or aspirin, 3-7 days following a myocardial 
infarction (MI) in the CADET trial. Treatment was continued for 6 months, with blood 
samples taken at randomisation, 1, 3 and 6 months for measurement of thrombotic risk 
factors and C-reactive protein. The study was designed to have 80% power of detecting 
a 10% reduction in Clauss fibrinogen level. 
Results: 46 subjects had a serious adverse event (22% on clopidogrel and 28% on aspi- 
rin), of which 8 were deaths (5% and 3%), and a further 11 (5% and 7%) were withdrawn 
from treatment. 39 (17% and 25%) had a cardiovascular event. One month after treat- 
ment both treatment groups had significantly (p<0.05) reduced Clauss fibrinogen 
(reduced, on average, by 20% on clopidogrel and 25% on aspirin), immunonephelomet- 
ric fibrinogen (14% and 14%), C-reactive protein (90% and 90%), fibrin D-dimer (29% 
and 26%), van Willebrand factor (23% and 28%) and factor VIII activity (19% and 18%). 
Only aspirin significantly reduced tissue plasminogen activator antigen (0.4% and 12%). 
Neither therapy significantly reduced plasma viscosity (0.0% and 1.6%). With the excep- 
tion of two isolated, marginal chance findings, there were no significant differences 
(p>0.05) between any of these variables between future clinic visits (1 to 3 or 3 to 6 
months). There were no significant differences (p>0.05) between clopidogrel and aspirin 
when comparing any of these variables at either 1 or at 6 months, adjusting for baseline 
differences. Further adjustment for age, sex, blood pressure, smoking, height and weight 
had no material affect on these results. 
Conclusion: Similar reductions in thrombotic risk factors and C-reactive protein following 
a MI were observed with clopidogrel and with aspirin. The higher efficacy of clopidogrer 
compared to aspirin may reflect other mechanisms. 
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1027-39 Too Litt le Aspirin for Secondary Prevention in High Risk 
Patients 
siroit Frillina, Rudolf Schiele, Ansalm Kai Gift, Steffen Schneider, Ralf Zahn, Jechen 
Senges, Staedtisches Klinikum Ludwigshafen, Ludwigshafen, Germany. 
Background: Large trials have shown a significant reduction of vascular mortality in 
patients(pts) receiving aspidn for secondary prevention after acute myocardial infarction 
(AMI). About 10% of these pts do not receive aspirin after discharge. Little is known of 
characteristics and Iongtime course of these pts. 
Methods: MITRA was a prospective multicenter egistry of 5370 pts with AMI in Germany 
with a mean follow-up of 18 months, 977 pts (18%) did not receive aspirin after dis- 
charge. 
Conclusions: 18% of AMI pts did not receive aspidn at discharge despite few contraindi- 
cations,The majority of the pts without aspirin were at high risc for cardiovascular events. 
The Iongterm mortality of pts without aspirin was almost two times higher than in pts with 
aspirin. 
MITRA 1994-1998 
no aspirin aspirin p-value 
age > 70 years 48.8% 32.1% < 0.001 
no reperfusion at AMt 54.9% 38.6% < 0,001 
history of AMI 21.4% 14.7% < 0,001 
recent stroke (<3months) 2.0% 0.9% 0.005 
diabetes 26.3% 19.8% < 0.001 
peptic ulcer 7.7% 3.2% < 0.001 
heart failure 43.3% 23.6% < 0.001 
renal insufficiency 3.8% 2.3% < 0.001 
mortality (18months) 19.2% 11,2% < 0.001 
non-fatal vascular event 12.8% 7.8% 0.02 
1027-40 Lower Myocardial Infarction Risk From Selective 
Serotonin Reuptake Inhibitors but Not Other 
Antidepressants 
William H. Sauer, Jesse A, Bedin, Stephen E. Kimmel, University of Pennsylvania School 
of Medicine, Philadelphia, Pennsylvania, Center for Clinical Epidemio/ogy and 
Biostatistics, Philadelphia, Pennsylvania. 
Background: Prior investigations have suggested that selective serotonin reuptake inhib- 
itors (SSRIs) may reduce myocardial infarction (MI) risk, perhaps via attenuation of sero- 
tonin-mediated platelet activation or treatment of depression, particularly in smokers. We 
sought to validate this finding, to examine the effect in non-smokers, and to examine the 
effects of non-SSRI antidepressants. 
Methods: A case-central study of first MI, ages 40 through 75, was conducted among 36 
hospitals in a 5-county area during a 28 month period. Cases were patients hospitalized 
with a first MI, and controls were randomly selected from the same geographic area. 
Detailed information regarding medication use and other clinical and demographic data 
were obtained by telephone interview. 
Results: 189 SSRI users were identified among the 909 cases and 3,030 controls who 
participated. After adjustment, using multivariable logistic regression, for age, gender, 
race, insurance status, exercise, body mass index, number of cigarettes smoked per day, 
family history, and history of coronary disease, diabetes, hypertension, and hypercholes- 
terolemia, the odds ratio (OR) for MI among SSRI users compared with non-antidepres- 
sant users was 0.31 (95% CI: 0.12, 0.78; P=0.01) in smokers and 130 (95% Ch 0.78, 
2.16; P=0.30) in non-smokers (test for interaction P<0.01). Smokers using SSRIs also 
had a reduced risk of MI relative to those using non-SSRI antidepressants (P<0.01). 
These non-SSRi antidepressant users did not have a reduced risk of MI compared to 
non-antidepressant users among either smokers or non-smokers (adjusted OR for smok- 
ers 1.67, CI: 0.79, 3.53; P=0.18; non-smokers 1.20, Ch 0.63, 2.28; P=0,58). 
Conclusion: The lower risk of MI associated with SSRI use is limited to smokers, and 
non-SSRIs are not associated with reduced risk. This suggests that attenuation of plate- 
let activation may be the reason for the association between SSRI use and MI protection. 
This benefit may be more apparent in smokers because of the altered platelet activity 
seen in this group. 
1027-41 Ef fects  of Zoloft~ on Platelet/Endothelial Biomarkers in 
Depressed Patients After Acute Coronary Events: 
Sertraline Anti-Depressant Heart Attack Randomized 
Trial (SADHART Platelet Substudy) 
Victor Serebruanv. Alexander Glassman, Alex Malinin, Ranga Krishnan, Milch Finkel, 
Charles Nemeroff, Paul Gurbel, Cathryn Clap/, Wilrna Harrison, Christopher O'Connor, 
Johns Hopkins University, Baltimore, Maryland, Duke University Medical Center, 
Durham, North Carolina. 
Background: Platelets could represent a missing link between incidence of depression 
and adverse clinical outcomes in patients after acute cardiovascular syndromes (ACS). 
However, it is still not clear how modem therapies of mood disorders including selective 
serotonin reuptake inhibitors (SSRI's) affect platelet function in such patients. We serially 
assessed release of established platelet/endothelial biomarkers in patients receiving ser- 
traline versus placebo in a frame of the SADHART trial. Methods: Plasma samples 
(baseline, week 6, and week 16) were collected from 5 sites in the US and Canada from 
patients treated with Zoloft (n=28), and placebo (n=36). Aspirin and clopidogrel were 
allowed in this study. Platelet factor 4 (PF4), b-thromboglobulin (bTG), platelet/endothe- 
lial cell adhesion molecule-1 (PECAM-1), P-selectin, thromboxane (TxB2), prostacyclin 
(6-keto-PGFla), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin were mea- 
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sured by ELISA. Results: At every time point after baseline for each biomarker mea- 
sured, patients undergoing treatment with sertraline exhibited substantially less platelet 
activation than those receiving placebo. These differences reached statistical signifi- 
cance for PF4 (p=0.03), and bTG (p=0.04) at week 4, and for bTG (p=0.02), PECAM-t 
(p=0.01), and P-selectin (p=0.02) at week 16 after randomization. There was a trend 
towards inhibition of prostanoids (TxB2, and 6-keto-PGFla), and endothelial-released 
adhesion molecules (VCAM-1, and E-selectin) in patients treated with sertraline as well, 
although these changes were not significant. Conclusion: Despite aggressive anti*plate- 
let regimens including aspirin and clopidogret, treatment with sertraline in depressed 
post-ACS patients is associated with the decreased release of platelet/endothelial biom- 
arkers. Mild antiplatelet properties of SSRI's may represent an attractive additional 
advantage for using these agents in patients with depression in the context of coronary 
artery disease and ischemic stroke. 
1027-42 The Association of Isosorbide-5-Monitrate to an ACE 
Inh ib i tor  Started Ear ly  Af ter  Myocardial Infarction 
Improves Left Ventricular Structure and Function Over 
Three Months: The Delepril and Remodelling in Acute 
Myocardial Infarction (DRAMI) Study 
Roberto Latini, Aldo P. Maggioni, Lidia Staszewskv. Violeta Labarta, Paolo Marino, 
Giovanni Cremonesi, Silvana Gramenzi, Giuseppe Sarcina, Sergio Piras, for the DRAMI 
Investigators,/stituto Mario Negri, Mi/ano, /taly, Centro Studi ANMCO, Firenze, Italy. 
Background. ACE inhibitor (ACEi) started early after AMI reduce moda~ity and morbidity. 
A subanalysis of the GISSi-3 study suggested additional benefit when a nitrate was 
associated to the ACEL DRAMI was a multicenter, randomised, double-blind study to (1) 
verify whether isosorbide-5-mononitrate (ISSMN) added to an ACEi enhances its benefi- 
cial effects on LV remodelling, and (2) assess the tolerability of a new ACEi, delapril (D), 
in comparison to lisinopril (L). 
Methods. 177 patients were randomised to D or L, with IS5MN or placabo (4 groups) 
within the first 36h of AMI symptoms, if they had at least 7 abnormal ECG leads and/or 
signs and symptoms of LV dysfunction, in absence of contraiodications. Study drugs 
were given for 3 mos, serial echocardiographic (echo) exams were done at the site and 
read by a core lab. 
Results. At randomization, 37% of the pts were in Killip class II and III, 81% received 
thrombolytics, 91% aspirin, 43% betablockers, 3-too incidence of the primary combined 
endpoint of mortality and serious clinical events was 38.4% and 31.9% in D and L (p=NS) 
and 35.6% and 35.5% in IS5MN and placebo, 3-mo mortality was 10.2%, without differ- 
ence between treatments. Mean (+/-SD) differences between 3-mo echo and baseline 
(D) are shown in the table. 
Conclusion. The systematic association of IS5MN to an ACEi significantly improves LV 
structure and function after AMI vs ACEi+placebo, without an excess of adverse reac- 
tions. 3-mo treatment with D or L is well tolerated when started within the first 36h after 
AMI. 
IS5MN placebo p (Wilcoxon) 
end diastolic vol 4.2±29.4 17.4±33.5 0.04 
end systolic vol -5.5±19.3 7.5±26.1 0.005 
ejection fraction 6.7¢8.2 1.9±8.8 0.01 
1027-43 Stroke Reduct ion  With Low-Medium Dose Warfar in/  
Aspirin Combination Following Myocardial Infarction in 
the CHAMP Study 
Jonathan F. Plehn. Ayumi K. Shintani, Michael D. Ezekowitz, Peter N. Peduzzi, Peter S. 
Rahko, Louis D. Flora, for the CHAMP Investigators, SL Francis Hospital, Roslyn, New 
York. 
Background: Following myocardial infarction (MI), 5,059 subjects (99% male, mean 
age=62 +10 years) were randomly assigned to either: a) warfarin and 81 mg/day of aspi- 
rin (WAR) with a target INR=1.5-2.5 or b) aspirin 162 mg/day alone (ASA) in the VA Com- 
bination Hemotherapy and Mortality Prevention (CHAMP) Study. As previously reported, 
all-cause mortality and MI recurrence were unaffected by treatment over a median fol- 
Iowup of 36 months. Because the value of routine, low-moderate l vel anticoagulation i
stroke prevention following MI has been controversial, we assessed the effect of WAR on 
stroke incidence in CHAMP. 
Results: By intention to treat analysis, subjects randomized to WAR had stroke inci- 
dence similar to ASA at 6, 12 or 36 months as indicated by relative risks (RR) and 95% 
confidence intervals (CI) which were non-significant (RR=0.91, CI 0.55, 0.91; RR=1.0, CI 
0.65,1.55; RR=0.89, CI 0.66-1.21, respectively). However, in on-traatment analysis, 
when stratified by lower and higher INRs (LWAR=<2.0, HWAR=>2.0 ), WAR had signifi- 
cant protective and apparent dose-ranging effects. Compared to ASA (n=2,537), LWAR 
subiects (n=1,301) with mean INR at 6 months=l.5 ± 0.3 experienced 2, 8 and 29 
strokes at 6, 12 and 36 months, respectively (RR=0.12, CI 0.03,0.50; RR=0.37, CI 
0.17,0.78; RR=0.60, CI 0.39,0.91) while HWAR (n=416) with mean INR =2.4+0.5 had 0 
strokes at 6 and 12 months (RR=0.0, CI 0,0 for both) and 5 strokes at 36 months 
(RR=0.33, CI 0.14,0.82) with first stroke occurrence at 401 days following randomization. 
Stroke incidence or treatment effect was unrelated to either ECG MI location (anterior/ 
septal vs. other MIs) or qualitative echo ejection fraction. 
Conclusions:l) By on-treatment analysis, low-medium dose warfarin/aspirin combina- 
tion significantly reduced stroke incidence compared to aspirin throughout he study 
duration, 2) Stroke reduction associated with WAR was greater when INR=_> 2.0 and was 
independent of infarct location or ventricular systolic function. 
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1027-44 Female Gender Does Not Impact Outcomes in Patients 
With Postinfarct Left Ventricular Dysfunction Treated 
With Carvedilol 
Willem J. Remme. Henry J. Dargie, lan Ford, Jose-Luis Lopez Sendon, Norman Sharpe, 
Antje Blank, on behalf of the CAPRICORN Investigators, Sticares Foundation, 
Rotterdam, The Netherlands. 
Background: CAPRICORN, a randomised double blind placebo-controlled study of 
carvedilol in patients with left vantricular dysfunction after myocardial infarction on ACE 
inhibition, demonstrated improvement in survival, non-fatal MI and in the combined end- 
point of cardiovascular mortality or non-fatal MI or hospitalisation for heart failure. 
Although conflicting, previous heart failure trials have suggested a sex/beta-blocker inter- 
action. This abstract aims to determine whether gender differences impact on the effects 
of carvedilol in CAPRICORN. Methods: 1959 patients with acute MI and an LV ejection 
fraction <= 40 % were included in 163 centres in 17 countries. 259 women and 716 men 
were randomised to carvedilo] and 260 and 724 respectively to placebo. Carvedilol did 
not affect withdrawal rates in either sex. Analyses were done on ITT basis and for time to 
first event. Mean follow-up was 1.3 years. Results: In women carvedilol reduced all- 
cause mortality by 27 %, HR 0.73 (95 % CI 0.49-1.09) and in men by 22 %, HR 0.78 
(0.58-1.06). The second co-primary endpoint all-cause mortality or cardiovascular hospi- 
talisations was reduced in women by 17 %, HR 0.83 (0.63-1.08) and in men by 3 %, HR 
0.97 (0.81-1.t5). All cause mortality or non-fatal MI was reduced by 32 % (0.46-0.98) in 
women and by 27 % (0.56-0.95) in men. Non-fatal MI was reduced by 25 % (0.34-1.66) 
in women and by 47 % (0.32-0.88) in men, whereas the combined endpoint of CV death 
or non-fatal MI or hospitalisation for heart failure decreased by 15 % (0.62-1.17) in 
women vs 21% (0.63-0.98) in men. Hospitalisation for heart failure fell by 11% (0.58- 
1.37) in women and by 16 % (0.62-1.13) in men. Interaction p values were all non signifi- 
cant. Conclusion: The analysed mortality and morbidity endpoints confirm that 
carvedilol had comparable effects in women and in men. Although women were under- 
represented as in most large scale trials, the consistent findings suggest a uniform pro- 
tective role for carvedilol irrespective of gender. 
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1049-31 Effects of Losartan and Quinapril on Myocardial Infarct 
Size and Endothelial Function 
Booino Zhu. Richard E. Sievers, Amanda E. Browne, Randall J. Lee, Kanu Chattejee, 
William Grossman, William W. Parmley, University of California, San Francisco, San 
Francisco, Cafifomia. 
Background:We previously showed that the angiotensin II receptor blocker Iosartan 
reduced infarct size and arrhythmias in a rat model of ischemia-raperfusion. The angio- 
tensin converting enzyme inhibitor quinapril has a strong affinity for tissue. We evaluated 
the individual and combined effects of Iosartan (L) and quinapril (Q) in a rat model of 
ischemia-repeffusion. Methods: Eighty Sprague-Dawley rats were randomized into 4 
groups: one control (C) and three pretreatment groups (L,Q,LQ) which were given 40 rag/ 
kg/day of Iosartan or/and 2.4 mg/kg/day of quinapri] in drinking water for 6 weeks respec- 
tively. After pretreatment, rats were subjected to 17 rain of LAD occlusion and 120 rain of 
reperfusion with hemodynamic and ECG monitoring. Results: Hemodynamic changes 
were the same, except group LQ had lower blood pressure. Effective refractory period 
(ERP) in the 4 groups were similar. Ventdcular fibrillation threshold (VFT) in the three pre- 
treatment groups was higher than controls. VF episodes per rat in the three pretreatmant 
groups were lower than controls. Infarct size was significantly reduced by Iosartan and 
Iosartan plus quinapril. Calcium ionophore (A23187) induced endothelium-dependent 
maximum vasorelaxation (Vasorelax) in groups L and LQ was higher than controls. Con- 
clusions: Six weeks of pretreatment with Iosartan and/or quinapril reduced arrbythmias; 
Iosartan or Iosartan plus quinapril decreased infarct size and increased endothelium- 
dependent vasorelaxation. 
(*P<O.05, **P<O.Ol when compared with the control group) 
Groups VFT(mA) VF Episodes infarct size(%) Vasorelax(%) 
Control (C) 0.36±0.05 2.4±0.2 43±4 -50±7 
Losartan (L) 1.27±0.25" 1.6±0.3* 30±6* -68±9" 
Quinapril (Q) 1.23±0.19" 1.1±0.3"* 43±3 -64±6 
Losartan+Quinapril (LQ) 1.29±0.39* 0.5±0.2** 30±4* -70±6" 
